
Program Memorandum Carriers

Department of Health &
Human Services (DHHS)
Centers for Medicare &
Medicaid Services (CMS)

Transmittal B-02-057

Date: SEPTEMBER 11, 2002

CHANGE REQUEST 2283

SUBJECT: Addition of Two “WW” Codes to Identify a New Source for Etoposide

Background

Suppliers are currently instructed to bill oral anti-cancer drugs to the DMERCs using the appropriate National Drug Code (NDC). The addition of these “WW” codes will allow the DMERCs to correctly adjudicate this oral anti-cancer drug. The proposed additions would read:

WW031 - Etoposide, 50mg, oral	(00378-3266-94, Mylan)
WW032 - Etoposide, 50mg, oral	(51079-0965-05, UDL)

Implementation

The DMERCs shall use the above “WW” codes for internal systems processing only and providers should still bill using the appropriate NDC codes for oral anti-cancer drugs.

The approval dates for Medicare coverage for the above sources of the drug etoposide are October 29, 2001 for UDL and November 15, 2001 for Mylan.

(DMEPOS category:9)(POS: 12,31,32,33,54,55,56)(TOS:9)

The *effective date* for this Program Memorandum (PM) is October 1, 2002.

The *implementation date* for this PM is October 1, 2002.

These instructions should be implemented within your current operating budget.

This PM may be discarded after October 1, 2003.

If you have any questions, contact Angie Costello at (410) 786-1554 or acostello@cms.hhs.gov.